Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Wedbush restated their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) in a research note released on Tuesday,Benzinga reports. Wedbush currently has a $18.00 price target on the stock. ARTV has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target […]
More Stories
Monthly Housing Payments Hit All-Time High, Home Affordability Affected
By Naveen Athrappully Americans now have to spend more money while buying homes as elevated property prices and mortgage rates...
Trump Inks $100 Million Deal With Skadden Law Firm
By Samantha Flom A prominent Wall Street law firm has struck a deal with the White House to provide $100...
Carney Says Trump ‘Respected Canada’s Sovereignty,’ Agreed to Negotiations During Call
By Matthew Horwood Prime Minister Mark Carney said his phone call with U.S. President Donald Trump was “substantive” and the...
North Carolina Supreme Court Rules That Family Can Sue Over Vaccination Without Consent
By Zachary Stieber A federal law granting broad immunity to vaccine administrators and others does not preempt charges that a...
Musk’s AI Startup Buys Social Media Platform X in $45 Billion Deal
By Tom Ozimek Elon Musk announced Friday that his artificial intelligence company, xAI, has acquired his social media platform X...
Xponance Inc. Buys 116 Shares of Alibaba Group Holding Limited (NYSE:BABA)
Xponance Inc. increased its stake in Alibaba Group Holding Limited (NYSE:BABA – Free Report) by 4.5% in the fourth quarter,...